NICE, medtech and evidence Mrs Mirella Marlow MA MBA Programme Director MediWales 11 December 2012.

Slides:

Advertisements

Similar presentations

Generating evidence to inform, difficult decisions: building capacity through investment and partnership Chris Henshall Pro Vice Chancellor for External.

Advertisements

Technology Appraisal of Medical Devices at NICE – Methods and Practice Mark Sculpher Professor of Health Economics Centre for Health Economics University.

Embedding Shared Decision Making – Lot 2 work programme.

NICE Guidance and Quality Standard on Patient Experience

Implementation of new technologies Dr Keith Cooper Southampton Health Technology Assessments Centre University of Southampton.

Highly Specialised Technologies Evaluations

Evidence in action – moving from guidance to review

SMC Evaluation Programme. Overview Context Evaluation Programme –Stakeholders –SMC advice Conclusions.

Using evidence to promote fast track adoption

CADTH Therapeutic Reviews

Cost-Effectiveness Analyses in the UK - Lessons from the National Institute for Clinical Excellence Mark Sculpher Professor of Health Economics Centre.

NICE in a changing world North East Leading Improvement for Health and Well- being programme Professor Mike Kelly Director, Centre for Public Health Excellence.

Cumbria Dementia Strategy Improving Recognition & diagnosis David Storm- Clinical Lead: Dementia Memory matters.

Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,

1Carl-Fredrik Burman, 11 Nov 2008 RSS / MRC / NIHR HTA Futility Meeting Futility stopping Carl-Fredrik Burman, PhD Statistical Science Director AstraZeneca.

NICE in a changing world National Leading Improvement for Health and Well-being programme 12 May 2011 Gillian Mathews Implementation consultant.

Decision Analysis as a Basis for Estimating Cost- Effectiveness: The Experience of the National Institute for Health and Clinical Excellence in the UK.

Standards Debate at the Centre for Better Managed Health Care, Cass Business School, City University London, 26 th October Professor Mike Kelly Director.

The National Institute for Clinical Excellence in the UK – Experience and Impact Mark Sculpher Professor of Health Economics Centre for Health Economics.

Introducing NICE... Gateshead Council Gillian Mathews Implementation consultant - north.

Assessing the value proposition and promoting the adoption of new and novel medical technologies Mark Campbell Associate Director Medical Technologies.

International Seminar SCIE’s approach to good practice 15 April 2009 Amanda Edwards, Deputy Chief Executive Patricia Kearney, Head of Children’s Services.

Access to Clinical Expertise Steve Bain David Powell Jemma Hughes Paula Jeffries.

Evidence based implementation for quality and health promotion in hospitals Professor Jos Kleijnen Director Centre for Reviews and Dissemination University.

Evaluation Trials and Studies Coordinating Centre 5 July 2013 NIHR Programmes and topic identification Alison Ford, Senior Programme Manager.

Innovation Pathway AHSN Stakeholder Event Russ Watkins Assistant Director – Business Innovation & Improvement Newcastle Hospitals.

NICE Decision Making Dr Katherine Payne North West Genetics Knowledge Park The University of Manchester

TECHNOLOGY APPRAISAL IN ACTION Mrs Karen Samuels Programme Manager.

NICE: what it is and how it works Professor David Haslam, Chair, NICE 10 th June 2015.

Working with NICE ADPH annual conference, Friday 11 th September 2009 Catherine Swann PhD CPsychol AFBPS Associate Director, Centre for Public Health Excellence.

A Regional Approach to Improvement Julie Branter Associate Director for Clinical Governance and Patient Safety 21 September 2010 South West Strategic Health.

NHS | Presentation to [XXXX Company] | [Type Date]1 Senates - the interface with SCNs and AHSNs Nigel Acheson Medical Director NHS England (South)

Health Technologies Adoption Programme Stephen Hodges – Technology Implementation Manager.

Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.

Transforming Community Services Commissioning Information for Community Services Stakeholder Workshop 14 October 2009 Coleen Milligan – Project Manager.

Developing a National Critical Care Clinical Research Network: what’s in it for trainees? Paul Dark Associate Professor, Faculty of Medical and Human Sciences,

Supporting tough decisions: linking Health technology assessment (HTA) and national priority setting in Norway Ånen Ringard 1, Berit Mørland 1,2 1 Secretariat.

Basic Economic Analysis David Epstein, Centre for Health Economics, York.

Plymouth Health Community NICE Guidance Implementation Group Workshop Two: Debriding agents and specialist wound care clinics. Pressure ulcer risk assessment.

Results The final report was presented to NICE and published by NICE and WHO. See

Evaluation, Trials and Studies Coordinating Centre Developing Sight Loss and Vision research questions: a funder’s perspective Anna Tallant Scientific.

“What’s in it for us?” NICE Guideline: Safe and Effective use of Medicines (Medicines Optimisation) Erin Whittingham Public Involvement Adviser Public.

How will we know whether this technology is appropriate? OR New procedures, NICE and Specialist Societies Bruce Campbell Chairman NICE Interventional Procedures.

Risk Sharing Schemes Dr Rafiq Hasan Director of Market Access

Process mapping of registration to reimbursement for new pharmaceuticals in UK.

HTA Efficient Study Designs Peter Davidson Head of HTA at NETSCC.

Simon Butler Centre Manager Funding Track record £7.8M.

Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,

Health Technology Assessment for Pharmaceuticals and New Medical Technologies - Where are we now? The industry perspective Jenny Hughes, Director, Vaccines.

Focus on health and care of mothers and infants ChiMat conference, 2009 Professor Mary Renfrew Mother and Infant Research Unit.

3 rd Annual Social Work Conference Quality social care for looked after young people Beth Anderson, Head of Research & Information Social Care Institute.

Introduction to NICE Professor David Haslam CBE Chair, NICE Student champion Study Day, January 2015.

Outline of the presentation

NIHR Invention for Innovation (i4i)

Introduction to NICE Professor David Haslam CBE Chair, NICE

Making NICE research nicer Involving patients, carers and the public

The NICE Citizens Council and the role of social value judgements

A Centre for New Methods in Computational Diagnostics and Personalised Therapy This EU H2020 ‘Teaming for Excellence’ project develops a Business Case.

Introduction to NICE Professor David Haslam CBE,

Dr Peter Groves MD FRCP Consultant Cardiologist

Research & scholarship

Working in Collaboration across the Health and Care System

An Introduction to the NIHR programmes

How to apply successfully to the NIHR HTA Board?

Professor of Health Economics

Dr Rosie Benneyworth Vice-Chair of NICE

NICE has many methods and processes

Process mapping of registration to reimbursement for new pharmaceuticals in UK Description: A systematic methodology was developed in order to create the.

Developing a Celtic Connections Regional HTA Alliance

Presentation transcript:

NICE, medtech and evidence Mrs Mirella Marlow MA MBA Programme Director MediWales 11 December 2012

Contents General information about NICE What do medtech products need to “prove”? How NICE works with medtech companies clarifying value propositions supporting development of evidence enhancing Health Technology Assessment (HTA) skills

About NICE National Institute for Health and Clinical Excellence Established in 1999 to reduce variation in the availability and quality of NHS treatments and care Guidance and evidence to support the health service and local authorities Independent of government New responsibilities from April 2013 – social care

BRAND MAP HERE 2012 NICE products & services

How can innovative medtech products help? (1) System benefits One-off device implant Reduce length of stay Different staff grade or type Reduce hospital- isation Speed up recovery

How can innovative medtech products help? (2) Patient benefits Decision or care nearer home Enable self care Enhance dignity Reduce unnecessary interventions Improve comp- liance

NICE works with companies Pre-evaluation Engagement team works with companies incl. SMEs Changing the view of the value proposition Encouraging development of evidence Exploring pipeline, focusing on clinical utility

How does NICE identify medical technologies for evaluation? Companies notify topics to NICE Test Device Medical Technologies Advisory Committee Medical technology guidance (MTEP) Diagnostics guidance (DAP) Tech Appraisals guidance (TAP)

NICE value proposition options Clinical performance BetterNon-inferior Cost HigherLess overall Evaluation method Cost effectiveness (QALY) Costs consequences (QIPP) NICE guidance programme Technology Appraisals Programme (TAP) Diagnostics Assessment Programme (DAP) Medical Technologies Evaluation Programme (MTEP) Technologies Devices Diagnostics Devices Diagnostics

Medical technologies guidance: ‘relevant’ evidence Sponsor submission ‒ Published and in-press trials ‒ Unpublished data ‒ Regulatory data ‒ Post-market register data, audits and ‘real-life’ experience ‒ Forthcoming trial results ‒ Planned trials in a reasonable timeframe Cost model Expert advice – clinical/patient ………Must support sponsor’s claim

NICE’s assessment of value Standard clinical evidence and health economic techniques ‒ Clinical evidence – systematic reviewing and meta-analysis, linked evidence approaches etc ‒ Health economics – modelling, sensitivity analysis etc World class academic assessment groups and external assessment centres Regular review of technical methods with stakeholders Further development of technical methods (e.g. MRC funded activities)

NICE medtech recommendations Evidence shows sufficient certainty of benefit Product has potential to provide substantial benefits, but uncertainty about whether these are realisable in normal clinical settings Significant uncertainty, or certainty of no benefit Case supported Adoption optimised OR Research recommended Case not supported Use (with standard NICE implementation or “deeper” adoption support - NTAC) Use in subgroup OR NICE/EAC supports development of evidenceNot for current use

Collaborating for better evidence Pre-evaluation: Advise companies to work with NOCRI on pipeline products Post-evaluation: Access to research facilitation for products with a research-only recommendation Pragmatic randomised controlled trial of MIST ultrasound therapy compared to UK standard care for the treatment of non-healing venous leg ulcers

Scientific advice seminars - medtech For developers and investors What is meant by value from the perspective of NICE? Know how your value proposition links to the need for specific evidence What is meant by cost effectiveness? Types of evidence considered by NICE General principles of health technology assessment (HTA)

Further information NICE website: Contact the NICE medtech team: Apply to attend a NICE medtech seminar: